Assessment of CymActive™ Catheter Technology for UrinAry ReTention and AcceptancE (The ACCTUATE Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

6 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-05-29

Study Completion Date

2025-10-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ACCTUATE study: Assessment of CymActive™ Catheter Technology for UrinAry reTention and acceptancE study will evaluate a novel catheter design that addresses the specific needs of male long term catheter users living in the community. The primary endpoint of the study will be tolerability, assessed by measuring patient-reported Quality of Life and VAS pain scale assessments up to approximately day 90 (end of study). The secondary endpoints will be comparisons of the Adverse Event nature and frequency, up to approximately 90 days (end of study) and genomic profiling of the abundance and diversity of microorganisms present in the screening visit urine sample versus the end of study urine sample of participants from both arms of the trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

AccuCath™ Intravenous (IV) Device Used by Vascular Access Team (VAT)

NCT01937195

Vascular Access Complication

COMPLETED NA

Effect of Active Drain Line Clearance on Catheter-Associated Bacteriuria

NCT03816384

Critical Illness Burns Surgery +2 more

WITHDRAWN NA

Rocamed Urethral Device (RUD) and Urinary Retention in Males

NCT04218942

Urinary Retention

COMPLETED NA

Study of the Criteria for Choosing Speedicath Catheters During the Initiation of Self-catheterization

NCT05065255

Urinary Retention

UNKNOWN

Performance of a Single-use Intermittent Micro-hole Zone Catheter

NCT05485922

Urinary Incontinence Retention, Urinary

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is an urgent need to address sub-optimal catheterisation that some men experience when living in the community with urinary retention problems. The catheters currently used within the NHS and in community settings are typically of the Intermittent or 'Foley' type. Foley type catheters are based on a nearly 100-year-old design, where an inflatable balloon, filled with water which anchors one end of the catheter within the bladder. At the other end, external to the body, a bag collects the urine, or a valve allows its discharge. Another option for patients requiring catheters is intermittent self-catheterisation. Intermittent catheters are single use, and self-catheterisation is needed multiple times per day, in order to empty the bladder. The number of times an intermittent catheter is used depends on the patient's condition and the frequency is guided by a Health Care Professional.

It is accepted that catheters in their current form, create a burden on the NHS, as Catheter Associated Urinary Tract Infections (CAUTI's) are one of the leading causes of healthcare-associated infections (HCAIs) and contribute significantly to mortality rates. Of Foley-type and intermittent users, the Foley- type catheters tend to lead to more infections.

The cymactive™ catheter (manufactured by Ingenion Medical Ltd) received CE marking on the 28th March 2024, as a Class IIb device (n. ECM24MDR002 rev.0, Single Registration Number (SRN) of the Manufacturer UK-MF-000041065). The cymactive™ catheter is designed to remain in situ for up to 30 days and does not extend outside the patient's body, except for two removal strings. The catheter has an integral, magnetically controlled valve that allows the user to control their own urination.

Study participants will be supplied with a magnetic Actuator (a separate Class I device supplied by Ingenion Medical), so they are in control of the valve and their own voiding.

The manufacturers of the cymactive™ catheter anticipate that the device may result in a better patient experience and potentially, a reduced risk of CAUTI when compared to a Foley catheter.

ACCTUATE is a multi-centre study, comparing the cymactive™ catheter device (CCD) versus Foley-type devices (FTD) in men with non-neurogenic urinary retention.

Study participants will be randomised (1:1) to receive either the cymactive™ catheter or a Foley catheter (the control arm) and the relevant catheter will be inserted on day 1 of the study. The cymactive™ catheters will be replaced approximately every 30 days, with a total study duration of approximately 90 days. Study participants randomised to the Active Comparator arm will receive the standard of care catheter (Foley) on day 1, for approximately 90 days. At the end of study visit (approx. day 90), CCD-treated subjects will undergo the removal of the CCD and a return to standard of care treatment, typically a FTD. However, as the cymactive™ device is CE marked, there is the possibility that the device may be available for post-study use, dependent upon clinical opinion and cymactive™ availability at specific institutions.

Approximately 60 participants will be recruited to this study; 30 patients in the CCD arm and 30 patients in the FTD arm.

The study will begin with the recruitment of a Sentinel group of 20 patients consisting of 10 patients randomised to the CCD arm and 10 patients randomised to the FTD arm. A review of the Sentinel group data, up to day 30 of the study, may be undertaken to examine any potential futility and/or safety signals. The Sentinel group will continue to participate in the study during this time as detailed in the Schedule of Activities.

Participants will be male adults (≥ 18 years) with a documented history of non-neurogenic urinary retention and long-term catheter use (\> or = 4 weeks).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Retention

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Two treatment arms with patients randomised 1:1, into treatment arm (cymactive™ catheter) and routine standard of care arm (Foley-type catheter).

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

cymactive™ catheter device (CCD) arm

Approximately 60 participants will be recruited to this study. Approximately 30 patients in the CCD arm.

Group Type EXPERIMENTAL

cymactive™ catheter device (CCD)

Intervention Type DEVICE

The cymactive™ catheter (manufactured by Ingenion Medical Ltd) received CE marking on the 28th March 2024, as a Class IIb device (n. ECM24MDR002 rev.0, Single Registration Number (SRN) of the Manufacturer UK-MF-000041065) and will be available in the UK market, subject to local arrangements.

The cymactive™ catheter is designed to remain in situ for up to 30 days, does not extend outside the patient's body except for 2 removal strings, and has an integral, magnetically controlled valve that allows the user to control their own urination. The study participant will each be supplied with a magnetic Actuator (a separate Class I device supplied by Ingenion Medical) so they are in control of valve and their own voiding. The magnet is strong and care will need to be taken to keep it at least 6 inches from magnetically-sensitive items, i.e. mobile phones, laptops and credit cards. Study participants should also avoid contact with MRI machines.

Foley-type device (FTD) arm

Approximately 60 participants will be recruited to this study. Approximately 30 patients in the FTD treatment group.

Group Type ACTIVE_COMPARATOR

Foley-type catheter device

Intervention Type DEVICE

Routine standard of care. Usually replaced \~ 3 monthly

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cymactive™ catheter device (CCD)

The cymactive™ catheter (manufactured by Ingenion Medical Ltd) received CE marking on the 28th March 2024, as a Class IIb device (n. ECM24MDR002 rev.0, Single Registration Number (SRN) of the Manufacturer UK-MF-000041065) and will be available in the UK market, subject to local arrangements.

The cymactive™ catheter is designed to remain in situ for up to 30 days, does not extend outside the patient's body except for 2 removal strings, and has an integral, magnetically controlled valve that allows the user to control their own urination. The study participant will each be supplied with a magnetic Actuator (a separate Class I device supplied by Ingenion Medical) so they are in control of valve and their own voiding. The magnet is strong and care will need to be taken to keep it at least 6 inches from magnetically-sensitive items, i.e. mobile phones, laptops and credit cards. Study participants should also avoid contact with MRI machines.

Intervention Type DEVICE

Foley-type catheter device

Routine standard of care. Usually replaced \~ 3 monthly

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants will be eligible to enrol in the study only if all of the following apply

* Male (anatomical)
* Adult, more than or equal to 18 years of age
* Capacity to give written informed consent
* Documented urinary retention, this may include patients who await a TURP, or similar, procedure
* Non-neurogenic urinary retention
* Catheter use on a long-term basis (\>4 weeks)

Exclusion Criteria

Participants will not be eligible to enrol in the study if any of the following apply

* Symptomatic bacteriuria (at screening)
* Surgical procedures performed in the lower urinary tract
* Neurogenic urinary retention
* Patients who have had a TURP (or similar) procedure
* Any malignancy in active/radical treatment (note: subjects with prostate or bladder cancer under surveillance only, may be enrolled into the study, at the Investigator's discretion)
* Patients who have a pacemaker or significant cardiovascular disease
* Participants with any contraindications, as outlined in the IFU
* Active participation in another interventional trial within the last 30 days
* Any condition, abnormality or issue, for which the investigator assesses the subject as unsuitable for an interventional study

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No